Health & Wellness Compass Pathways, Hackensack Meridian Health collaborate on psilocybin treatment research Partnership signals a milestone agreement for innovative treatment solutions Zartasha MushtaqJanuary 19, 2024
Psychedelics AI shows potential for predicting psilocybin therapy outcomes: COMPASS study The paper in the journal Psychopharmacology concluded that a machine learning algorithm could predict treatment efficacy Rowan DunneSeptember 8, 2023
Psychedelics Psilocybin-like drug may help people suffering from anorexia: COMPASS study The majority of participants reported significant improvements in their overall mental health Rowan DunneJuly 28, 2023
Psychedelics COMPASS Pathways reports 52% YoY cash loss The company had $126.6M less last quarter than it did in Q1 last year Rowan DunneMay 12, 2023
Psychedelics International psychedelics market to reach US$8.3B by 2027: ReportLinker The market was valued at US$4.83B this year and will rise with a CAGR of 14.5 per cent Rowan DunneApril 24, 2023
Canada Filament Health to supply psilocybin for federally-funded psychedelics clinical trial The trial is the first psilocybin study funded by the Canadian Institutes of Health Research (CIHR) Natalia Buendia CalvilloNovember 17, 2022